Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.54 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748948 | 0.89 | KMT2A (0.66) | MAPTRXFP1SYKKMT2AMEN1 | |
| SCHEMBL22982424 | 0.89 | KMT2A (0.66) | MAPTRXFP1SYKKMT2AMEN1 | |
| SCHEMBL23009587 | 0.89 | FOXM1 (0.59) | MAPTRXFP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL23009459 | 0.88 | LIMK1 (0.66) | MAPTRXFP1SYKKMT2AMEN1 | |
| SCHEMBL23009470 | 0.87 | KMT2A (0.67) | MAPTRXFP1SYKKMT2AMEN1 | |
| SCHEMBL23009440 | 0.82 | MAPT (0.59) | MAPTRXFP1SYKKMT2AMEN1 | |
| SCHEMBL29727500 | 0.82 | MAPT (0.59) | MAPTRXFP1SYKKMT2AMEN1 | |
| SCHEMBL23009519 | 0.79 | LMNA (0.67) | MAPTRXFP1SYKKMT2AMEN1 | |
| SCHEMBL23009467 | 0.78 | KMT2A (0.73) | MAPTRXFP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL24989165 | 0.78 | SYK (0.46) | MAPTRXFP1SYKKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387378-A1 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2025-12-25 | — | — | US | claimed |
| EP-4013408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | Hadasit Medical Research Services and Development Ltd. (IL) | 2022-06-22 | — | — | EP | claimed |
| WO-2021028919-A1 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2021-02-18 | — | — | WO | claimed |
| US-20250387378-A1 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2025-12-25 | — | — | US | disclosed |
| EP-4013408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | Hadasit Medical Research Services and Development Ltd. (IL) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021028919-A1 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028919-A1 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387378-A1 | METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS | EGFR, ERBB2, ERBB3 | MAPT 794/4885RXFP1 3386/4885SYK 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.